HOME >> BIOLOGY >> NEWS
Study of genomic DNA leads to new advances in cancer diagnostics

CHICAGO, Ill. -- Researchers at the University of Illinois at Chicago have identified a method of assessing the malignant potential of cells based on the sensitivity of cellular DNA to enzyme digestion. The article by Andrew J. Maniotis et al., "Chromatin sensitivity to Alu I restriction enzyme decreases with malignancy and is regulated by the extracellular matrix and cytoskeleton," appears in the April 2005 issue of The American Journal of Pathology and is accompanied by a commentary.

Using an enzyme (Alu I) that cuts DNA at a common sequence in the human genome, Dr. Maniotis's group classified cells based on sensitivity or resistance to DNA digestion. Non-malignant cells were sensitive to DNA digestion by Alu I while highly malignant cells were resistant. These results suggest that a cell's DNA, or chromatin, is protected during malignancy. This effect was confirmed using three pairs of cell types (normal melanocytes and melanoma cells, normal breast epithelium and breast carcinoma cells, and normal fibroblasts and fibrosarcoma cells) and diagnostic biopsy samples.

Will these methods help clinicians in diagnosing cancer? Because the investigators utilized several practical methods in their study, potential exists for future diagnostic applications. The cell smear assay, which is similar to methods commonly used in diagnostics laboratories (such as Pap smears), could be applied to such a purpose. The authors also used flow cytometry to characterize melanomas of varying invasiveness. Further study will be required to determine the specificity and sensitivity of these methods before they are used in the clinical setting.

Physicians and researchers alike know that how a cancer cell interacts with its microenvironment is important for cancer progression. Such interactions must be aberrant for abnormal cell growth and metastasis to occur. Indeed, Dr. Maniotis and his colleagues found that the extracellular matrix (ECM), or the mi
'"/>

Contact: Sharon Butler
sbutler@uic.edu
312-355-2522
American Journal of Pathology
22-Mar-2005


Page: 1 2

Related biology news :

1. Study begins to reveal clues to the cause and progression of sepsis
2. Study finds gender differences in renal and other genes contributing to blood pressure
3. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
4. Study: Sticking to the sand might not be such good, clean fun for beachgoers
5. Study points to new way to predict death risk from torn aorta
6. Study identifies new gene therapy tools for inherited blindness
7. Study finds contaminated water reaching Floridas offshore keys
8. Study sheds light on why humans walk on two legs
9. Study explains how pathogens evolve to escape detection
10. Study finds hereditary link to premenstrual depression
11. Study identifies energy efficiency as reason for evolution of upright walking

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study genomic DNA leads new advances cancer diagnostics

(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
(Date:5/23/2013)... for the overall health, development, and academic success ... in ensuring that all students have opportunities to ... of vigorous or moderate-intensity physical activity, says a ... Recent estimates suggest that only about half of ... better health and development. The report recommends ...
(Date:5/23/2013)... treating cerebral palsy with autologous cord blood. Following a ... old boy had been in a persistent vegetative state ... after treatment with the cord blood containing stem cells, ... child learned to speak simple sentences and to move. ... dispel the long-held doubts about the effectiveness of the ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
(Date:5/24/2013)... BOSTON and TEL AVIV, Israel ... ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in ... , the Company,s President and Chief Executive Officer, and ... will participate in the Benchmark Company, LLC One-on-One Investor Conference ... East Wisconsin Ave., Milwaukee, WI. ...
(Date:5/24/2013)... May 24, 2013 Many factors impact ... uptake or efflux transporters at the blood-tissue barrier. Even ... to unbound fractions in the tissue rather than the ... disposition challenges is required to guide lead optimization, predict ... any species-dependent variables that may impact the likely human ...
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
Cached News: